4.6 Article

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

期刊

BMC CANCER
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12885-021-08922-1

关键词

Rectal cancer; Neoadjuvant therapy; Pathological complete response; Tumor regression grade; Survival

类别

资金

  1. Major Scientific and Technological Special Project of Liaoning Province of China [2019JH1/10300007]
  2. Project of Oversea Training in University of Liaoning Province [2019GJWYB022]
  3. Liaoning Province Central Guided Local Science and Technology Development Special Fund [2018107004]
  4. Natural Science Foundation of Liaoning Province of China [2019-MS-390]

向作者/读者索取更多资源

The study found that patients with rectal cancer achieving pathologic complete response (pCR) had significantly higher 10-year overall survival and 5-year disease-free survival compared to those in the non-pCR group. Improvement in tumor regression after neoadjuvant therapy was associated with increased overall survival and disease-free survival, and the pCR group had longer overall survival and disease-free survival than the non-pCR group. The results suggest a positive relationship between better tumor regressions and improved survival benefits, highlighting the importance of achieving pCR in the treatment of rectal cancer.
Background Neoadjuvant therapy can lead to different tumor regression grades (TRG) in rectal cancer after neoadjuvant therapy. The purposes of this study are to investigate the relationships among TRG, pathologic complete response (pCR) and long-term survival, on the basis of reconstructed individual patient data (IPD). Methods The PubMed, Embase, Ovid and Cochrane CENTRAL databases were searched. The primary endpoint was to evaluate the survival landscape of different TRGs after neoadjuvant therapy and the secondary endpoint was to evaluate the associations between pCR and survival. IPD were reconstructed with Kaplan-Meier curves. Results The 10-year overall survival (OS) and 5-year disease-free survival (DFS) were clearly higher in the pCR group than in the non-pCR (npCR) group (80.5% vs. 48.3, 90.1% vs. 69.8%). Furthermore, the OS and DFS increased with improvement in tumor regression after neoadjuvant therapy. According to the IPD, the pCR group had longer OS (HR = 0.240, 95% CI = 0.177-0.325, p < 0.001) and DFS (HR = 0.274, 95% CI = 0.205-0.367, p < 0.001) than the npCR group. Better tumor regression was associated with better survival outcomes (p < 0.005). Direct calculation of published HR values yielded similar results. Conclusions Our results indicate a positive relationship between better tumor regressions and improved survival benefits among the npCR group and patients with rectal cancer achieving pCR had much longer OS and DFS than patients achieving npCR, presenting a survival landscape of different TRGs and pCR in rectal cancer after neoadjuvant therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据